Evidence map›Paper›PMID 17069463›Full record

ArticlePLoS genetics2006

RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism.

Azamat Aslanukov, Reshma Bhowmick, Mallikarjuna Guruju, John Oswald, Dorit Raz, Ronald A Bush, Paul A Sieving, Xinrong Lu, Cheryl B Bock, Paulo A Ferreira

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The SUMO Pathway.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Insights in Post-Translational Modifications: Ubiquitin and SUMO.International journal of molecular sciences · 2022
    Review
  18. RANBP2 ActivatesCancers · 2021
    Article
  19. Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Azamat AslanukovThird Wave Technologies, Madison, Wisconsin, United States of America.
Reshma Bhowmick
Mallikarjuna Guruju
John Oswald
Dorit Raz
Ronald A Bush
Paul A Sieving
Xinrong Lu
Cheryl B Bock
Paulo A Ferreira
Duke Medical Center · USNational Eye Institute · USDuke University Hospital · USMedical College of Wisconsin · USNational Institutes of Health · USThird Wave Systems (United States) · US

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
Retinal Degeneration--genetic/environmental animal modelZ01DC000065 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI SIEVING, PAUL · 2002 to 2008
$2.5M
STRUCTURE/FUNCTION ANALYSIS OF RANBP2 IN THE NEURORETINAR01EY011993 · NEI · MEDICAL COLLEGE OF WISCONSIN · PI FERREIRA, PAULO A · 1999 to 2006
$1.8M
Moleclar Pathogenesis of Retinitis Pigmentosa Type 3R01EY012665 · NEI · MEDICAL COLLEGE OF WISCONSIN · PI FERREIRA, PAULO A. · 2001 to 2004
$1.2M
NEI NIH HHS 2P30-EY005722-21NEI NIH HHS EY012665NEI NIH HHS EY11993NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY011993NEI NIH HHS R01 EY012665
6 · The paper itself

Abstract

The Ran-binding protein 2 (RanBP2) is a large multimodular and pleiotropic protein. Several molecular partners with distinct functions interacting specifically with selective modules of RanBP2 have been identified. Yet, the significance of these interactions with RanBP2 and the genetic and physiological role(s) of RanBP2 in a whole-animal model remain elusive. Here, we report the identification of two novel partners of RanBP2 and a novel physiological role of RanBP2 in a mouse model. RanBP2 associates in vitro and in vivo and colocalizes with the mitochondrial metallochaperone, Cox11, and the pacemaker of glycolysis, hexokinase type I (HKI) via its leucine-rich domain. The leucine-rich domain of RanBP2 also exhibits strong chaperone activity toward intermediate and mature folding species of Cox11 supporting a chaperone role of RanBP2 in the cytosol during Cox11 biogenesis. Cox11 partially colocalizes with HKI, thus supporting additional and distinct roles in cell function. Cox11 is a strong inhibitor of HKI, and RanBP2 suppresses the inhibitory activity of Cox11 over HKI. To probe the physiological role of RanBP2 and its role in HKI function, a mouse model harboring a genetically disrupted RanBP2 locus was generated. RanBP2(-/-) are embryonically lethal, and haploinsufficiency of RanBP2 in an inbred strain causes a pronounced decrease of HKI and ATP levels selectively in the central nervous system. Inbred RanBP2(+/-) mice also exhibit deficits in growth rates and glucose catabolism without impairment of glucose uptake and gluconeogenesis. These phenotypes are accompanied by a decrease in the electrophysiological responses of photosensory and postreceptoral neurons. Hence, RanBP2 and its partners emerge as critical modulators of neuronal HKI, glucose catabolism, energy homeostasis, and targets for metabolic, aging disorders and allied neuropathies.

Indexed as

HaploidyAmino Acid SequenceAnimalsCells, CulturedCopper Transport ProteinsElectron Transport Chain Complex ProteinsElectroretinographyGlucoseHexokinaseHSP70 Heat-Shock ProteinsMembrane ProteinsMiceMice, Mutant StrainsMitochondrial ProteinsModels, BiologicalMolecular ChaperonesCopper Transport ProteinsCox11 protein, mouseElectron Transport Chain Complex ProteinsGlucoseHexokinaseHK1 protein, mouseHSP70 Heat-Shock ProteinsMembrane ProteinsMitochondrial ProteinsMolecular ChaperonesNuclear Pore Complex Proteinsran-binding protein 2

Identifiers

PMID17069463
PMCPMC1626108
OpenAlexW2014358539

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.